Clinical evaluation of intradermal vaccination against porcine enzootic pneumonia (Mycoplasma hyopneumoniae)

Abstract

The aim of the present study was to investigate the efficacy of single-dose intradermal vaccination against Mycoplasma hyopneumoniae on a commercial swine unit. A total of 1051 healthy suckling piglets of 28±3 days of age were randomly assigned to one of three experimental groups: (a) intradermal: 346 piglets vaccinated intradermally (Porcilis M Hyo ID Once, Intervet SPAH), (b) intramuscular : 351 piglets vaccinated intramuscularly (Porcilis M1 Intervet SPAH) and (c) controls: 354 piglets injected with a placebo (adjuvant only). Performance parameters such as average daily weight gain (ADG), as well as health parameters and lung lesion scores were monitored from four weeks of age until slaughter. The improvement in ADG over the controls, during the finishing phase, was 27 g/day for the intradermal group and 17 g/day for the intramuscular group. Both intradermal and intramuscular vaccinations were effective in reducing clinical signs and lung lesions caused by M hyopneumoniae. Compared with the controls, approximately 10.4 per cent fewer clinical cases were diagnosed in the intradermal group, and 6 per cent fewer in the intramuscular group, during the finishing period. In conclusion, performance results were better in the vaccinated groups than in the control group, while intradermal vaccination afforded greater protection than intramuscular vaccination, especially with regard to morbidity, lung lesion and pleuritis scores.

Field efficacy study of a novel ready-to-use vaccine against mycoplasma hyopneumoniae and porcine circovirus type 2 in a Greek farm

“…Economical impact of M. hyo and PCV2 infections in swine farms worldwide can be considered as significant [1, 2]. Enzootic pneumonia (EP) is a major clinical respiratory disease in swine [3]. It is characterized by non-productive cough, growth retardation with higher feed conversion and decreased body weight gain and craneo-ventral pulmonary consolidation.…”

“…A number of previously reported studies have emphasized the benefits from such routine vaccination programmes either after intramuscular [10, 11] or intradermal administration [3, 11], against the negative impact of EP on health and productive parameters of infected pigs. However, despite the extensive vaccination efforts in the vast majority of swine farms worldwide, M. hyo remains a major problem [12].…”

Vector optimization and needle-free intradermal application of a broadly protective polyvalent influenza A DNA vaccine for pigs and humans

“…The IDAL Ò device is developed for use in pigs and has previously only been used in pig studies. [33][34][35][36] The immunization of rabbits with the IDAL Ò device was successful in the current study and the desired deposition of the vaccine into the dermis layers was evaluated immediately after injections with colored liquid in a single rabbit (Fig. 2).…”

“…Different needle-free injection systems have been tested successfully with influenza DNA plasmids in animals 21,32 and humans. 11 The needle-less IDAL Ò vaccinator (MSD Animal Health, Summit, NJ, US) is already used routinely for vaccination in swine herds for attenuated and inactivated protein vaccines against the Porcine Reproductive and Respiratory Syndrome virus, 33 Aujeszky's disease virus 34 and Mycoplasma hyopneumoniae 35,36 with promising results. Previously, we have demonstrated cross-protective immunity in ferrets and pigs from DNA vaccines with pandemic genes of the 1918 H1N1-, 1968 H3N2-and pdm09 H1N1-influenza virus.…”

“…The IDAL Ò device is successfully used for the vaccination of swine. 33,34,36 DNA immunization of New Zealand White (NZW) rabbits Ten-week-old female nulliparous NZW rabbits were housed at Statens Serum Institute Animal Facility (Copenhagen, Denmark). Animal experiments were performed by certified animal handlers and according to the Animal Experimentation Act of Denmark and European Convention ETS 123.…”